Journal Article

Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin

Cosgrove, Casey, O’Malley, David M., Suarez, Adrian, Zingarelli, Roman, Bognar, Balazs, Sakaue, Takahiko, Cohn, David E., Khadraoui, Wafa, Wanner, Ross, Maxwell, G. Larry, Anbalagan, Muralidharan, Dorayappan, Kalpana Deepa Priya, Wallbillich, John, Koga, Hironori, Selvendiran, Karuppaiyah

2024

Overview

Endometrial cancer (EC) is the leading gynecologic malignancy in the United States with obesity implicated in 57% of cases. This research investigates the molecular complexities of extracellular vesicles (EV) secretion as carriers of oncogenic protein and their involvement in obesity-mediated EC. An understanding of these mechanisms is pivotal for unraveling pathways relevant to obesity-associated EC, thereby guiding the development of innovative prevention and treatment strategies. Our exploration revealed a significant increase in EV secretion carrying oncogenic proteins (TMEM205, STAT5, and FAS) in adipose and uterine tissues/serum samples from obese EC patients compared to control (without cancer). We identified alterations in EV-regulating proteins (Rab7, Rab11, and Rab27a) in obesity-mediated EC patients, adipose/uterine tissues, and serum samples. Through a 24-week analysis of the effects of a 45% kcal high-fat diet (HFD) on mice, we observed increased body weight, increased adipose tissue, enlarged uterine horns, and increased inflammation in the HFD group. This correlated with elevated levels of EV secretion and increased expression of oncogenic proteins TMEM205, FAS, and STAT5 and downregulation of the tumor suppressor gene PIAS3 in adipose and uterine tissues. Furthermore, our study confirmed that adipocyte derived EV increased EC cell proliferation, migration and xenograft tumor growth. Additionally, we identified that the small molecule inhibitors (HO-3867) or Metformin inhibited EV secretion in vitro and in vivo, demonstrating significant inhibition of high glucose or adipocyte-mediated EC cell proliferation and a reduction in body weight and adipose tissue accumulation when administered to HFD mice. Moreover, HO-3867 or Metformin treatment inhibited HFD induced hyperplasia (precursor of EC) by altering the expression of EV-regulated proteins and decreasing oncogenic protein expression levels. This study provides critical insights into the mechanisms underpinning obesity-mediated EV secretion with oncogenic protein expression, shedding light on their role in EC pathogenesis. Additionally, it offers pre-clinical evidence supporting the initiation of novel studies for EV-targeted therapies aimed at preventing obesity-mediated EC.

• Publisher: Nature Publishing Group UK,Nature Publishing Group
• Subject: 631/67 / 631/67/1517/1709 / Adipocytes / Adipose tissue / Animals / Antidiabetics / Apoptosis / Body fat / Body weight / Cell Biology / Cell growth / Cell Line, Tumor / Cell migration / Cell proliferation / Cell Proliferation - drug effects / Diet, High-Fat - adverse effects / Endometrial cancer / Endometrial Neoplasms - drug therapy / Endometrial Neoplasms - metabolism / Endometrial Neoplasms - pathology / Endometrium / Extracellular vesicles / Extracellular Vesicles - metabolism / Female / High fat diet / Human Genetics / Humans / Hyperplasia / Internal Medicine / Malignancy / Medicine / Medicine & Public Health / Metformin / Metformin - pharmacology / Metformin - therapeutic use / Mice / Obesity / Obesity - drug therapy / Obesity - metabolism / Oncology / Pathogenesis / Patients / Protein expression / Proteins / Secretion / Stat5 protein / Tumor suppressor genes / Tumors / Uterine cancer / Uterus